Poolbeg’s cytokine release syndrome drug shows potential
17th January 2024 Uncategorised 0Data supports Poolbeg’s strategic expansion of POLB 001 More: Poolbeg’s cytokine release syndrome drug shows potential Source: News
read more
Data supports Poolbeg’s strategic expansion of POLB 001 More: Poolbeg’s cytokine release syndrome drug shows potential Source: News
read moreGilead calls off Oceanside manufacturing expansion, uproots biologics development team mbayer Tue, 01/16/2024 – 15:48 More: Gilead calls off Oceanside manufacturing expansion, uproots biologics development team Source: fierce
read moreVertex, CRISPR’s gene-editing therapy Casgevy wins early FDA nod to treat beta thalassemia kdunleavy Tue, 01/16/2024 – 15:11 More: Vertex, CRISPR's gene-editing therapy Casgevy wins early FDA nod to treat beta thalassemia Source: fierce
read moreProminent German trade union pushes back on potential Bayer split: Reuters zbecker Tue, 01/16/2024 – 10:44 More: Prominent German trade union pushes back on potential Bayer split: Reuters Source: fierce
read moreTakeda picks up 2nd FDA-approved indication for immune globulin treatment HyQvia kdunleavy Tue, 01/16/2024 – 10:36 More: Takeda picks up 2nd FDA-approved indication for immune globulin treatment HyQvia Source: fierce
read moreGSK pumps £200M+ into UK manufacturing network to bolster commercial ambitions, API supply fkansteiner Tue, 01/16/2024 – 10:19 More: GSK pumps £200M+ into UK manufacturing network to bolster commercial ambitions, API supply Source: fierce
read more© 1994 - 2026 B.M. Pharmaceuticals